Lurbinectedin for extensive stage − small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes
Lurbinectedin demonstrated meaningful clinical activity in second-line therapy for SCLC, while also showing durable responses in heavily pretreated cases. These findings support the consideration of lurbinectedin also beyond second-line therapy in selected SCLC patients, though larger prospective studies are needed to validate these response patterns.
Authors
- Roni Gillis (ORCID: https://orcid.org/0000-0001-6226-2573)
- Jair Bar (ORCID: https://orcid.org/0000-0002-1224-3646)
- Hadas Sorotsky (ORCID: https://orcid.org/0000-0003-3310-970X)
- Laila C. Roisman (ORCID: https://orcid.org/0000-0001-8455-9327)
- Ofer Rotem (ORCID: https://orcid.org/0000-0001-7821-9625)
- Gleb Kornev
- Bilal Krayim
- Ekaterina Hanovich
- Nir Peled (ORCID: https://orcid.org/0000-0003-3714-4377)
- Noam Asna (ORCID: https://orcid.org/0009-0007-1720-069X)
- Waleed Kian (ORCID: https://orcid.org/0000-0003-4956-9364)
- Walid Shalata (ORCID: https://orcid.org/0000-0002-7570-4550)
- Shir Mann
- Rose Marie
- Damian Urban
- Mor Moskovitz
- Afifi Basel
Institutions
- Ben-Gurion University of the Negev (IL)
- Sheba Medical Center (IL)
- Rabin Medical Center (IL)
- Assuta Medical Center (IL)
- Soroka Medical Center (IL)
- Shaare Zedek Medical Center (IL)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108598
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09